Sireen Abdulrahim Shilbayeh

Prof. Sireen Abdulrahim Shilbayeh

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2017 in International Journal of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
SSSireen Abdulrahim Shilbayeh
Sireen Abdulrahim Shilbayeh
WAWejdan Ali Almutairi
Wejdan Ali Almutairi
SASarah Ahmed Alyahya
Sarah Ahmed Alyahya
NANouf Hayef Alshammari
Nouf Hayef Alshammari
ESEiad Shaheen
Eiad Shaheen
AAAlya Adam
Alya Adam

1 September 2018 in Value in Health Regional Issues
Verified
Journal Article
Closed access
SSSireen Abdulrahim Shilbayeh
Sireen Abdulrahim Shilbayeh
SASarah Ahmed Alyahya
Sarah Ahmed Alyahya
NANouf Hayef Alshammari
Nouf Hayef Alshammari
WAWejdan Ali Almutairi
Wejdan Ali Almutairi
ESEiad Shaheen
Eiad Shaheen

6 July 2020 in Health and Quality of Life Outcomes
Verified
Journal Article
Open access
PDF file
SSSireen Abdulrahim Shilbayeh
Sireen Abdulrahim Shilbayeh
AIAlnada Ibrahim
Alnada Ibrahim
Background: Long-term anticoagulation therapy, particularly with warfarin, is usually associated with poor adherence and low patient satisfaction. However, previous studies have highlighted the possibility that individual perceptions of warfarin differ according to cultural practices. This study validated the psychometric properties of the translated Arabic version of the Anti-Clot Treatment Scale (ACTS) for patients on warfarin therapy in Saudi Arabia. Methods: A cross-sectional multicenter study was conducted at the three main medical centers in Riyadh. Stratified sampling was employed to recruit Arabic-speaking patients who had been taking warfarin for a minimum of 3 months for any indication. The patients completed the specific ACTS along with the generic Treatment Satisfaction Questionnaire for Medication (TSQM 1.4) at two clinic visits. The psychometric performance of the ACTS was evaluated using well-established criteria: feasibility, reliability, and validity. Results: One hundred thirty-six patients participated in the study (mean age: 50.68 ± 14.6 years; range: 19–97). Overall, the patients reported moderate Burdens and Benefits scores (44 ± 9.9 and 11.92 ± 2.4, respectively) compared to the reference range for each subscale (12–60 and 3–15, respectively); however, they reported lower Burdens scores than other populations. Consistent with the original ACTS validation study, the criteria for acceptability (data targeting, floor/ceiling effects, and skewness) were satisfied; in fact, the Arabic version exhibited better item- and scale-level distributions of data than versions in other languages. The ACTS subscales also demonstrated satisfactory test-retest reliability with significant intraclass correlation coefficients ((ICC ≥ 0.5); p < 0.001) and good internal consistency (all Cronbach’s alpha values exceeded 0.7). Exploratory factor analysis supported the 2-factor loading model. Interestingly, the Arabic version exhibited greater convergent validity with the TSQM subdomains (r = 0.61). Conclusions: This study provides convincing evidence that the Arabic versions of both the ACTS Burdens and ACTS Benefits scales are equivalent to other versions in terms of psychometric performance, as measured using reliability and validity criteria. These properties support the great potential of the Arabic ACTS to accurately reflect patient satisfaction, identify aspects of treatment that need improvement in clinical practice, and compare treatment satisfaction across different anticoagulant therapies or cultures in research.

5 February 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
SSSireen Abdulrahim Shilbayeh
Sireen Abdulrahim Shilbayeh
IAIman Sharaf Adeen
Iman Sharaf Adeen
EGEzzeldeen Hasan Ghanem
Ezzeldeen Hasan Ghanem
HAHaya Aljurayb
Haya Aljurayb
KAKhawlah Essa Aldilaijan
Khawlah Essa Aldilaijan
AFAbeer Fadda
Abeer Fadda
Background: Autism spectrum disorders (ASDs) encompass a broad range of phenotypes characterized by diverse neurological alterations. Genomic studies have revealed considerable overlap between the molecular mechanisms implicated in the etiology of ASD and genes involved in the pharmacokinetic (PK) and pharmacodynamic (PD) pathways of antipsychotic drugs employed in ASD management. Given the conflicting data originating from candidate PK or PD gene association studies in diverse ethnogeographic ASD populations, dosage individualization based on “actionable” pharmacogenetic (PGx) markers has limited application in clinical practice. Additionally, off-label use of different antipsychotics is an ongoing practice, which is justified given the shortage of approved cures, despite the lack of satisfactory evidence for its safety according to precision medicine. This exploratory study aimed to identify PGx markers predictive of risperidone (RIS) exposure in autistic Saudi children.Methods: This prospective cohort study enrolled 89 Saudi children with ASD treated with RIS-based antipsychotic therapy. Plasma levels of RIS and 9-OH-RIS were measured using a liquid chromatography–tandem mass spectrometry system. To enable focused exploratory testing, genotyping was performed with the Axiom PharmacoFocus Array, which included a collection of probe sets targeting PK/PD genes. A total of 720 PGx markers were included in the association analysis.Results: A total of 27 PGx variants were found to have a prominent impact on various RIS PK parameters; most were not located within the genes involved in the classical RIS PK pathway. Specifically, 8 markers in 7 genes were identified as the PGx markers with the strongest impact on RIS levels (p < 0.01). Four PGx variants in 3 genes were strongly associated with 9-OH-RIS levels, while 5 markers in 5 different genes explained the interindividual variability in the total active moiety. Notably, 6 CYP2D6 variants exhibited strong linkage disequilibrium; however, they significantly influenced only the metabolic ratio and had no considerable effects on the individual estimates of RIS, 9-OH-RIS, or the total active moiety. After correction for multiple testing, rs78998153 in UGT2B17 (which is highly expressed in the brain) remained the most significant PGx marker positively adjusting the metabolic ratio. For the first time, certain human leukocyte antigen (HLA) markers were found to enhance various RIS exposure parameters, which reinforces the gut–brain axis theory of ASD etiology and its suggested inflammatory impacts on drug bioavailability through modulation of the brain, gastrointestinal tract and/or hepatic expression of metabolizing enzymes and transporters.Conclusion: Our hypothesis-generating approach identified a broad spectrum of PGx markers that interactively influence RIS exposure in ASD children, which indicated the need for further validation in population PK modeling studies to define polygenic scores for antipsychotic efficacy and safety, which could facilitate personalized therapeutic decision-making in this complex neurodevelopmental condition.

5 November 2020 in Cogent Psychology
Verified
Journal Article
Open access
SSSireen Abdulrahim Shilbayeh
Sireen Abdulrahim Shilbayeh
SISahar Abd El Rahman Ismail
Sahar Abd El Rahman Ismail
Evidence-based guidelines recommend that patient knowledge should be considered an essential component in oral anticoagulation treatment (OAT) to improve adherence and subsequent clinical outcomes. Therefore, a mobile health (mHealth) technology-based educational intervention using smartphone features could be a promising approach for patients receiving OAT. However, mobile applications (mApps) developed in this context are rare, and there is still a lack of research examining the perceived usability of these apps from end-users’ perspectives and the feasibility of implementing them in daily clinical practice for chronic OAT end-users. In this study, we developed a novel mApp educational tool about OAT (warfarin) and evaluated the perceived usability of this app among Saudi adult patients. In addition, the impact of the app intervention on anticoagulation control parameters was examined. The Coagulation and Anticoagulant Therapy and Awareness (CATA) mApp was developed by a collaborative effort from a multidisciplinary team using the Android system. The mApp content was processed using an intuitive user-friendly interface containing simple Arabic text. The app was uploaded to the mobile phones of patients who were randomly selected from two medical centers in Riyadh, Saudi Arabia. Usability evaluation was conducted after 6 months post-mApp intervention, using a comprehensive questionnaire that addressed five main dimensions of participants’ perceived usability of the mApp: attractiveness, ease of use, satisfaction, operability, and presentation quality. Thirty-seven participants (Mage = 45 years) completed the usage survey. The mean overall usability score (76.8%) demonstrates that most participants were satisfied with the CATA mApp and found it useful. Of the five user experience domains examined, patients expressed the highest agreement score for the presentation quality domain (79.5%), reflecting the attractiveness of the visual appearance and logic of information demonstration of the app. Additional themes were identified by some users in the free-text questions, indicating that further unique features such as longer audiovisual demonstrations and direct web browser facility should be added to ensure sustained engagement with the app in their daily routines. Regarding international normalized ratio (INR) control parameters, no significant changes were observed. Further feedback from practitioners is warranted to gain constructive insights into the facilitators and barriers for mApp implementation in routine care. Additionally, the current data revealed that there are concerns about increasing INR control via the incorporation of a computing tool that empowers patient data entry and doctor sharing of patient records. These features are projected to ultimately bridge the gap between patient adherence and clinical outcomes.

1 January 2020 in Journal of Pharmacy and Bioallied Sciences
Verified
Journal Article
Open access
PDF file
SSSireen Abdulrahim Shilbayeh
Sireen Abdulrahim Shilbayeh
Context: Internationally, various warfarin education strategies have been described in the medical literature and delivered by a variety of health-care providers. However, none of these were tested in a Saudi setting. Aim: The aim of this study was to assess the impact of pharmacist interventions via an educational video on improving patient knowledge of and satisfaction with warfarin therapy and the international normalized ratio (INR). Setting and Design: This study adopted a prospective pre- and posttest design and enrolled 91 patients from an anticoagulant clinic at King Khaled University Hospital in Riyadh, Saudi Arabia, between September 2017 and February 2018. Materials and Methods: All patients completed the Anticoagulation Knowledge Assessment (AKA) and Anti-Clot Treatment Satisfaction (ACTS) scales. Subsequently, the patients watched a 10-min educational video containing basic information regarding warfarin and were given relevant informative booklets. The patients were reassessed after a mean follow-up period of approximately 52 days. Results: In total, 85 patients completed the study. The impact of the intervention on patient knowledge was highly significant (mean difference = 17.7%, 95% confidence interval (CI) = 21.75–13.58, P < 0.000). In addition, the patients showed significant increases in their ACTS benefits subscale scores (mean difference = 0.73, 95% CI = 1.22–0.24, P = 0.004). Despite being long-term warfarin users, the patients’ INRs had a greater tendency to be within the target range after the intervention (56.63% ± 35% vs. 64.72% ± 35% of the time; mean difference, 8.1 percentage points; effect size = 0.23). However, there was no significant effect on patients’ perceptions of the warfarin burden. Conclusion: This study provided evidence that a pharmacist-led audiovisual intervention via an educational video coupled with an informational booklet effectively improved patients’ knowledge retention and satisfaction with warfarin therapy benefits. Longer studies are needed to determine the impact of this intervention on patients’ perceptions of warfarin burdens and their INRs.